These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 24029000)

  • 41. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tuberculosis during TNF-α inhibitor therapy, despite screening.
    Hofland RW; Thijsen SF; Verhagen MA; Schenk Y; Bossink AW
    Thorax; 2013 Nov; 68(11):1079-80. PubMed ID: 23598710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Rev Port Pneumol; 2006; 12(5):603-13. PubMed ID: 17117328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
    Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
    J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.
    To KW; Reino JJ; Yoo DH; Tam LS
    Respirology; 2013 Jul; 18(5):765-73. PubMed ID: 23627398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.
    Sellam J; Hamdi H; Roy C; Baron G; Lemann M; Puéchal X; Breban M; Berenbaum F; Humbert M; Weldingh K; Salmon D; Ravaud P; Emilie D; Mariette X;
    Ann Rheum Dis; 2007 Dec; 66(12):1610-5. PubMed ID: 17456528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.
    Ai JW; Zhang S; Ruan QL; Yu YQ; Zhang BY; Liu QH; Zhang WH
    J Rheumatol; 2015 Dec; 42(12):2229-37. PubMed ID: 26472414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test.
    Laffitte E; Janssens JP; Roux-Lombard P; Thielen AM; Barde C; Marazza G; Panizzon RG; Saurat JH
    Br J Dermatol; 2009 Oct; 161(4):797-800. PubMed ID: 19659473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis of latent tuberculosis infection (LTBI) before anti-TNF-alpha treatment--the tuberculin skin test is useful.
    Goujon C; Nosbaum A; Bensaid B; Rozières A; Nicolas JF; Bérard F
    Eur J Dermatol; 2012; 22(5):701-2. PubMed ID: 23032063
    [No Abstract]   [Full Text] [Related]  

  • 52. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
    Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
    J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease.
    Bassukas ID; Kosmidou M; Gaitanis G; Tsiouri G; Tsianos E
    Acta Derm Venereol; 2011 Jun; 91(4):444-6. PubMed ID: 21547342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist.
    Lee J; Kim E; Jang EJ; Lee CH; Lee EY; Im JP; Han SK; Yim JJ
    Ann Am Thorac Soc; 2017 May; 14(5):690-697. PubMed ID: 28253020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
    Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.
    Martin J; Walsh C; Gibbs A; McDonnell T; Fearon U; Keane J; Codd MB; Dodd J; Veale D; Fitzgerald O; Bresnihan B
    Ann Rheum Dis; 2010 Jan; 69(1):181-5. PubMed ID: 19176545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.
    Kang J; Jeong DH; Han M; Yang SK; Byeon JS; Ye BD; Park SH; Hwang SW; Shim TS; Jo KW
    J Korean Med Sci; 2018 Nov; 33(47):e292. PubMed ID: 30450023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tuberculosis risk in patients with rheumatologic disease treated with biologic drugs.
    Argüder E; Yanık Üstüner G; Ekici R; Kılıç H; Erten Ş; Karalezli A
    Tuberk Toraks; 2020 Sep; 68(3):236-244. PubMed ID: 33295721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.
    Yoo JW; Jo KW; Kang BH; Kim MY; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Eur Respir J; 2014 Nov; 44(5):1289-95. PubMed ID: 25102962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
    Denis B; Lefort A; Flipo RM; Tubach F; Lemann M; Ravaud P; Salmon D; Mariette X; Lortholary O;
    Clin Microbiol Infect; 2008 Feb; 14(2):183-6. PubMed ID: 18076664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.